
|Videos|June 6, 2017
Comparing Bosutinib Versus Imatinib in Newly Diagnosed CML
Author(s)Jorge Cortes, MD
Jorge Cortes, MD, deputy chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses initial results from the BFORE trial, which is exploring bosutinib (Bosulif) versus imatinib (Gleevec) for newly diagnosed chronic myeloid leukemia.



















